NEW DRUG DEVELOPMENT

STRAGEN New Drug Development identifies promising patented compounds from biotechnology start-ups as well as academic institutions and develops these into drugs of high therapeutic potential.
STRAGEN designs and conducts the full development programme, from pre-clinical to manufacturing scale-up, paving the way to global registration.

STR-324 PAIN

A first-in-class non-opioid painkiller with a safe, non-addictive, and innovative mode of action. STR-324 is the synthetic equivalent of natural human peptides inhibiting the degradation of endogenous painkillers, showing efficacy on acute and prolonged pain without the common side effects of opioids (animal models).